Small-molecule inhibitors of ALKBH5 have been developed in recent years and have been shown to be effective in the treatment of various diseases, including AMI, AKI, AML, melanoma and glioblastoma (Table 3) [125–132]. This evidence concerns the gene ALKBH5 and acute myeloid leukemia.